February 2024 in “Sučasna gastroenterologìâ” The patient was diagnosed with celiac disease after a long delay, showing the need for better awareness and earlier detection.
90 citations
,
May 1972 in “Clinical Pharmacology & Therapeutics” Minoxidil quickly leaves blood, turns into urine metabolites, and has lasting blood pressure-lowering effects.
19 citations
,
October 2008 in “Journal der Deutschen Dermatologischen Gesellschaft” Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
CRPS I is complex, linked to immune and nerve issues, and needs comprehensive treatment.
16 citations
,
October 2023 in “Molecular cancer” New treatments like nanotechnology show promise in improving skin cancer therapy.
December 2023 in “The journal of physical chemistry. B (1997 : Online)” Human hair keratin might be good for filtering out harmful substances from water.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
1 citations
,
October 2024 in “Journal of the Endocrine Society” Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.
2 citations
,
February 2024 in “Toxins” Bee venom can help stem cells promote hair growth.
Bee venom can improve various skin conditions, including varicose veins and psoriasis, and has anti-aging benefits.
September 2013 in “Oncology Times” Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.
34 citations
,
April 1982 in “BMJ” 6 citations
,
September 2024 in “Current Oncology” Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
November 1993 in “Hair transplant forum international” The document's conclusion cannot be provided because the document is not readable or understandable.
November 2004 in “Oncology Times” Advocacy groups should avoid marketing partnerships that may imply drug endorsements.
Health warnings can increase product sales over time.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
April 2012 in “Dermatology Times E-News” Finasteride must now warn about lasting sexual side effects.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
4 citations
,
January 2015 in “Case Reports in Urology” Venlafaxine can cause urinary incontinence in rare cases.
1 citations
,
April 2002 in “PubMed” Anti-epileptic drugs may cause visual and hair side effects due to enzyme inhibition, especially in genetically predisposed individuals.
October 2022 in “Research Square (Research Square)” The conclusion is that certain chemicals from Bacillus subtilis help improve plant root growth through a hormone-related process.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
May 2010 in “Europe PMC (PubMed Central)” Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.